Anant Gokarn

Anant Gokarn

Auto-generated profile, based on publicly available information

Anant Gokarn

BMT Unit, Department of Medical Oncology Tata Memorial Centre, ACTREC Navi Mumbai Maharashtra India

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
ARAkhil Rajendra
Akhil Rajendra
HJHasmukh Jain
Hasmukh Jain
VBV. N. Avinash Bonda
V. N. Avinash Bonda
LNLingaraj Nayak
Lingaraj Nayak
PTPrashant Tembhare
Prashant Tembhare
MSManju Sengar
Manju Sengar
The use of pediatrics-inspired protocols in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) results in superior survival compared with the adult protocols. Pediatrics-inspired protocols carry an increased risk of toxicity and treatment-related mortality in low resource settings, which can offset the potential benefits. We studied the outcomes and prognostic factors in the treatment of AYA ALL with a pediatrics-inspired regimen. We retrieved data regarding demographics, investigations, treatment details, and toxicities from the electronic medical records of patients diagnosed with ALL in the 15- to 25-year-old age group who were initiated on a modified Berlin-Frankfurt-Münster 90 (BFM-90) protocol between January 2013 and December 2016 at the Tata Memorial Centre. A total of 349 patients in the 15- to 25-year-old age group were treated with a modified BFM-90 protocol. The use of this pediatrics-inspired protocol resulted in a 3-year event-free survival (EFS) and overall survival (OS) of 59.4% and 61.8%, respectively. Only 15 patients underwent an allogeneic stem cell transplant. Minimal residual disease (MRD) persistence postinduction emerged as the only factor predictive of poor outcomes. A modified BFM-90 protocol is an effective and safe regimen for AYA ALL with an OS and EFS comparable to the published literature.

7 December 2014 in Chemotherapy Research and Practice
Verified
Journal Article
Open access
PDF file
VNVanita Noronha
Vanita Noronha
AJAmit Joshi
Amit Joshi
AGAnant Gokarn
Anant Gokarn
VSVibhor Sharma
Vibhor Sharma
VPVijay Patil
Vijay Patil
KPKumar Prabhash
Kumar Prabhash
Introduction. Brain metastasis is a poor prognostic marker in lung cancer. However it is not known whether amongst patients with EGFR mutation those with brain metastases have a worse outcome. Methods. We compared the survival outcomes between EGFR mutation positive patients with and without brain metastases. In this retrospective analysis of prospective database of all metastatic lung cancer patients at our centre between July 2009 and December 2012, patients were treated with either combination chemotherapy or oral TKI. All patients with brain metastases received whole brain radiation. Kaplan Meier method was used for survival analysis and compared using log rank test. Results. 101 patients with EGFR mutated, metastatic lung cancer were studied. Fourteen had brain metastases and 87 did not. The common EGFR mutations were exon 19 deletion (61.3%) and exon 21 L858R mutation (28.7%). Overall response was 64% in extracranial metastasis group as compared to 50% in brain metastasis group. There was a significant worsening of median OS in the patients with brain metastases (11.6 months) compared with only extracranial metastases (18.7 months), . Conclusion. Amongst patients with EGFR mutant NSCLC, the presence of brain metastases leads to a worse outcome as compared to patients with extracranial metastases alone.

9 September 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
AGAnant Gokarn
Anant Gokarn
PTPrashant R. Tembhare
Prashant R. Tembhare
HSHasan Syed
Hasan Syed
ISIsha Sanyal
Isha Sanyal
RKRohit Kumar
Rohit Kumar
NKNavin Khattry
Navin Khattry
Long-term cryopreservation of peripheral blood stem cells (PBSCs) is highly useful in the setting of tandem/multiple transplants, or treatment of relapse in autologous transplant setting. Even in allogeneic transplants donor lymphocyte infusions may be stored for months to years if excess stem cells are collected from donors. Cryopreservation is a delicate, complex, and costly procedure and higher concentrations dimethyl sulfoxide (DMSO), which is a commonly used cryo-protectant, can be toxic to cells and cause adverse effects to the recipient during infusions. We studied the effect of long-term cryopreservation using 4.35% DMSO (as final concentration) with methyl cellulose, using uncontrolled rate freezing in a mechanical freezer (-80 C), on the viability and colony-forming ability of CD34+ human PBSC. To study the long-term viability of PBSCs cryopreserved using 4.35% DMSO and stored at -800 C in a mechanical freezer. In this study, stem cells for patients undergoing autologous transplants were cryopreserved using DMSO (final concentration of 4.35%) with methyl cellulose. Post-thaw viability of PBSCs was determined using Trypan-blue-exclusion and flow cytometry-based 7-amino-actinomycin-D (FC-7AAD) methods. Concentration of CD34+ stem cells (SC) and immune-cell subsets in post-thaw PBSC-harvest samples were assessed using multicolor flow cytometry and the clonogenic potential of post-thaw stem cells was studied using colony-forming-units (CFU) assay. The CD34+SC levels were correlated with the pre-storage CD34 levels using the Pearson correlation test. The viability results were compared between the Trypan Blue dye exclusion method and the flow cytometry-based method using Bland-Altman plots. We studied 26 PBSC harvest samples with a median cryopreservation duration of 6.6 years (range, 3.8-11.5 years). Median viability of post-thaw PBSC was >80% using both methods with a weak agreement between them (r=0.03; p=0.5). Median CD34+SC counts in post-thaw samples was 9.13 × 106/Kg (range, 0.44 × 106/Kg - 26.27 × 106/Kg). CFU assay yielded a good proliferation and differentiation potential in post-thaw PBSCs with a weak correlation between the number of CFU-GM and CD34+SC levels (r=0.4, p=0.05). Two samples which were cryopreserved for > 8 years showed low viability. Cryopreservation of PBSC using a 4.35% DMSO with methyl cellulose using uncontrolled freezing in a mechanical freezer at -80°C allows the long-term viability of PBSC to be maintained for up to a period of 8 years.

1 December 2021 in JCO Global Oncology
Verified
Journal Article
Open access
SBSuresh Kumar Bondili
Suresh Kumar Bondili
BBBhausaheb Bagal
Bhausaheb Bagal
AZAbhinav Zawar
Abhinav Zawar
PVPradeep Ventrapati
Pradeep Ventrapati
JTJayashree Thorat
Jayashree Thorat
NKNavin Khattry
Navin Khattry
PURPOSE: The prognosis of relapsed and refractory multiple myeloma (RRMM) that is refractory to bortezomib and lenalidomide is very poor wherein the median survival is between 3 and 9 months. We did this retrospective analysis to study the pattern of utilization, tolerance, and outcomes with pomalidomide in these patients having RRMM. MATERIALS AND METHODS: Retrospective analysis of all the patients who were treated with generic pomalidomide at Tata Memorial Centre, Mumbai, during the period of May 2017 to March 2019 was done. Patients with secretory disease and who had completed at least one cycle of pomalidomide were analyzed for response rates, toxicity, and survival outcomes. RESULTS: A total of 81 patients received pomalidomide-based therapy during this study period, out of which 75 were included in the survival analysis. Forty-eight patients (59.3%) were refractory to both lenalidomide and bortezomib. Overall response rate was 58.7%. Five patients (6.7%) achieved complete response, very good partial response was seen in 13 patients (17.3%), and partial response was seen in 26 patients (34.7%). After a median follow-up of 11 months (range 2-27 months), median progression-free survival was 9.1 months (95% CI, 5.4 to 12.9 months). Median progression-free survival for patients who were refractory to both lenalidomide and bortezomib versus nonrefractory was 5.5 and 12.6 months, respectively, which was significant statistically ( P = .04, hazard ratio, 0.35, 95% CI, 0.28 to 0.97). The median overall survival was not reached. Important toxicities included anemia (28%), neutropenia (16%), pneumonia (16%), and venous thrombosis (5%). CONCLUSION: Generic pomalidomide-based therapy is an effective option and is well tolerated in patients with RRMM. Higher response rates and longer survival seen in our study are possibly because of heterogeneity of the study population.

1 December 2012
Verified
Journal Article
Closed access
AGAnant Gokarn
Anant Gokarn
MNMeenakshi Gangadhar Narkhede
Meenakshi Gangadhar Narkhede
GPGeeta Shrikar Pardeshi
Geeta Shrikar Pardeshi
MDMohan Kondiba Doibale
Mohan Kondiba Doibale

23 January 2025 in Cytotherapy
Verified
Journal Article
Closed access
AGAnant Gokarn
Anant Gokarn
LRLaxma Reddy
Laxma Reddy
SHSumathi Hiregoudar
Sumathi Hiregoudar
MPMinal Poojary
Minal Poojary
SPSarika Parab
Sarika Parab
NKNavin Khattry
Navin Khattry